Pharmacokinetic-pharmacodynamic model of the antihypertensive interaction between telmisartan and hydrochlorothiazide in spontaneously hypertensive rats
Authors:
Open Access
- 17 March 2014
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 66 (8) , 1112-1121
Abstract
Objectives: The goal of this study was to establish an integrated indirect response pharmacokinetic-pharmacodynamic model between telmisartan and hydrochlorothiazide to describe the antihypertensive interaction of these two drugs in spontaneously hypertensive rats.Methods: The blood pressure and plasma concentrations were measured by the tail-cuff test and high performance liquid chromatographyߝmass spectrometry, respectively, in spontaneously hypertensive rats. The current pharmacokinetic–pharmacodynamic model was based on the non-competitive pharmacodynamic interaction of two drugs acting on different physiological processes.Key findings: This model was able to acquire the temporal changes in drug concentration and blood pressure after administration of telmisartan or hydrochlorothiazide. The noncompetitive pharmacodynamic interaction assumed that the decreased blood pressure was attributed to the inhibitory function of telmisartan and stimulatory function of hydrochlorothiazide after administration of these two drugs. There was no significant pharmacokinetic change of telmisartan and hydrochlorothiazide in the different groups tested. The model predicted a synergistic pharmacodynamic interaction when telmisartan was administered in combination with hydrochlorothiazide, which was notably stronger than if the effects were additive.Conclusion: The results showed that the presented pharmacokinetic-pharmacodynamic model was suitable for describing the antihypertensive interaction between telmisartan and hydrochlorothiazide.Keywords
Funding Information
- Project Program of State Key Laboratory of Natural Medicines (02410346)
- Jiangsu Province Key Lab of Drug Metabolism and Pharmacokinetics Projects (BM2012012)
- Natural Science Foundation of Jiangsu (SBK201240220)
- Natural Science Foundation of China (81302839)
This publication has 21 references indexed in Scilit:
- PK/PD modelling and simulations: utility in drug developmentDrug Discovery Today, 2008
- Model-based Drug DevelopmentClinical Pharmacology & Therapeutics, 2007
- Determination of telmisartan in human plasma by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2005
- Telmisartan/hydrochlorothiazide: a new fixed dose combinationExpert Review of Cardiovascular Therapy, 2005
- Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate HypertensionHypertension Research, 2005
- Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertensionExpert Opinion on Pharmacotherapy, 2004
- Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) studyJournal Of Hypertension, 2004
- Comparative bioavailability of two immediate release tablets of enalapril/hydrochlorothiazide in healthy volunteersEuropean Journal of Drug Metabolism and Pharmacokinetics, 2002
- Safety and Tolerability of Eprosartan in Combination with HydrochlorothiazideDrug Safety, 2002
- Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive ratsJournal of the Renin-Angiotensin-Aldosterone System, 2001